Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants

针对SARS-CoV-2多种变种的刺突蛋白RBM特异性人类抗体的结构基础

阅读:5
作者:Kiyomi Shitaoka #,Akifumi Higashiura #,Yohei Kawano #,Akima Yamamoto,Yoko Mizoguchi,Takao Hashiguchi,Norihisa Nishimichi,Shiyu Huang,Ayano Ito,Shun Ohki,Miyuki Kanda,Tomohiro Taniguchi,Rin Yoshizato,Hitoshi Azuma,Yasuo Kitajima,Yasuyuki Yokosaki,Satoshi Okada,Takemasa Sakaguchi,Tomoharu Yasuda

Abstract

The decrease of antibody efficacy to mutated SARS-CoV-2 spike RBD explains the breakthrough infections and reinfections by Omicron variants. Here, we analyzed broadly neutralizing antibodies isolated from long-term hospitalized convalescent patients of early SARS-CoV-2 strains. One of the antibodies named NCV2SG48 is highly potent to broad SARS-CoV-2 variants including Omicron BA.1, BA.2, and BA.4/5. To reveal the mode of action, we determined the sequence and crystal structure of the Fab fragment of NCV2SG48 in a complex with spike RBD from the original, Delta, and Omicron BA.1. NCV2SG48 is from a minor VH but the multiple somatic hypermutations contribute to a markedly extended binding interface and hydrogen bonds to interact with conserved residues at the core receptor-binding motif of RBD, which efficiently neutralizes a broad spectrum of variants. Thus, eliciting the RBD-specific B cells to the longitudinal germinal center reaction confers potent immunity to broad SARS-CoV-2 variants emerging one after another.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。